Top

International Urogynecology Journal

Published in:

01-07-2010 | Original Article

Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status

Authors: Marc R. Toglia, Donald R. Ostergard, Rodney A. Appell, Masakazu Andoh, Allam Fakhoury, Iqbal F. Hussain

Published in: International Urogynecology Journal | Issue 7/2010

Abstract

Introduction and hypothesis

VENUS evaluated the efficacy of solifenacin on urgency in patients with overactive bladder (OAB). We hypothesized that solifenacin would be comparably efficacious in continent and incontinent patients.

Methods

VENUS was a 12-week, placebo-controlled trial in patients with OAB. Treatment efficacy was assessed using bladder diaries and patient-reported outcome measures. The primary endpoint was the change in daily urgency episodes. Exploratory subgroup analyses were conducted using baseline continence status.

Results

Solifenacin reduced urgency episodes versus placebo in continent (−3.4 vs. −2.3) and incontinent patients (−4.2 vs. −2.9) and incontinence episodes (−2.1 vs. −1.2) in that subgroup; 58% versus 42% of incontinent patients receiving solifenacin versus placebo were continent at study end. In both cohorts, solifenacin- versus placebo-treated patients showed greater improvements in perceptions of urgency severity, symptom bother, and health-related quality of life.

Conclusion

This post hoc analysis demonstrates the efficacy of solifenacin regardless of baseline continence status.

Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P (2006) Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 25:293CrossRef

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178CrossRefPubMed

Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F et al (2005) The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95:335–340CrossRefPubMed

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315CrossRefPubMed

Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–766CrossRefPubMed

Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–336PubMed

Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562CrossRefPubMed

Abrams P, Swift S (2005) Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 48:483–487PubMed

Nitti VW, Dmochowski R, Appell RA, Wang JT, Bavendam T, Guan Z (2006) Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 97:1262–1266CrossRefPubMed

10.

Michel MC, de la Rosette JJ, Piro M, Schneider T (2005) Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol 48:110–115CrossRefPubMed

11.

Rovner ES, Rackley R, Nitti VW, Wang JT, Guan Z, 037 Study Group (2008) Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. Urology 72:488–493CrossRefPubMed

12.

Cardozo L, Lisec M, Millard R, van Vierssen TO, Kuzmin I, Drogendijk TE et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172:1919–1924CrossRefPubMed

13.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310CrossRefPubMed

14.

Gittelman M, Chu FM, Klimberg I, Fincher R, Smith N, Tempel D et al (2003) Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multi-center studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder [abstract DP43]. J Urol 169:349

15.

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73:14–18CrossRefPubMed

16.

Toglia MR, Serels SR, Laramee C, Karram MM, Nandy IM, Andoh M et al (2009) Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med 121:151–158CrossRefPubMed

17.

Cardozo L, Dixon A (2005) Increased warning time with darifenacin: a new concept in the management of urinary urgency. J Urol 173:1214–1218CrossRefPubMed

18.

Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, Staskin DR et al (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174:604–607CrossRefPubMed

19.

Cardozo L, Coyne KS, Versi E (2005) Validation of the urgency perception scale. BJU Int 95:591–596CrossRefPubMed

20.

Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079–1086CrossRefPubMed

21.

Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563–574CrossRefPubMed

22.

Cardozo L, Castro-Diaz D, Gittelman M, Ridder A, Huang M (2006) Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 17:512–519CrossRefPubMed

23.

van Leeuwen JH, Castro R, Busse M, Bemelmans BL (2006) The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 50:440–452, discussion 453CrossRefPubMed

Title: Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status
Authors: Marc R. Toglia
Donald R. Ostergard
Rodney A. Appell
Masakazu Andoh
Allam Fakhoury
Iqbal F. Hussain
Publication date: 01-07-2010
Publisher: Springer-Verlag
Published in: International Urogynecology Journal / Issue 7/2010
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-010-1120-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction and hypothesis

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2010

An uncommon case of urethrovaginal fistula resulting from tension-free vaginal tape

Rectovaginal fistula model in the New Zealand white rabbit

Erratum to: Genome-based expression profiles study for the pathogenesis of pelvic organ prolapse: an array of 33 genes model

Uterus conserving prolapse surgery—what is the chance of missing a malignancy?

Vaginal flap re-enforcement of vesico-vaginal fistula repair

Single incision mini-sling versus a transobutaror sling: a comparative study on MiniArc™ and Monarc™ slings